Company intelligence / Profile preview
TeraImmune
Gaithersburg, Maryland, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
TeraImmune was a private biotech company focused on developing advanced regulatory T cell (Treg)-based cell therapies for autoimmune and immune-mediated diseases. Its lead candidate, TI-168, an autologous T cell receptor-engineered Treg therapy for hemophilia A with inhibitors, received FDA IND clearance and is in Phase 1/2a clinical trials. The company's proprietary platform technologies, TREGable™ and TREGing™, enabled both autologous and allogeneic Treg approaches, with additional preclinical programs for multiple sclerosis and atopic dermatitis. TeraImmune was acquired by Baudax Bio in June 2023.
- Therapeutic areas
- ImmunologyHematologyNeurologyDermatology
- Modalities
- Cell therapyAutologous T cell therapyAllogeneic T cell therapyRegulatory T cell (Treg) therapyT cell receptor-engineered T cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
National Institute of Allergy and Infectious Diseases (NIAID)NIH/NIAID Cooperative Research and Development Agreement (CRADA)
Beyond the preview
Go deeper on TeraImmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TeraImmune.